Gene M. Dubowchik
Research Subjects
Research Interests
Gene M. Dubowchik has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Alexander Vinitsky
Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 5100, Wallingford, Connecticut 06492-7660, and P.O. Box 4000, Princeton, New Jersey 08543-4000
2 shared publicationsDavid Willner
Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 5100, Wallingford, Connecticut 06492
2 shared publicationsJodi A. Michne
Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 5100, Wallingford, CT 06492-7660, USA
2 shared publicationsSagarika Bollini
Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 5100, Wallingford, Connecticut 06492-7660, and P.O. Box 4000, Princeton, New Jersey 08543-4000
2 shared publicationsBireshwar Dasgupta
Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 5100, Wallingford, Connecticut 06492-7660, and P.O. Box 4000, Princeton, New Jersey 08543-4000
1 shared publicationClint A. James
Bristol-Myers Squibb Pharmaceutical Research Institute, Candiac, Quebec, Canada J5R 1J1
1 shared publication
Latest Publications
- 26 September 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (22) , 3997-4000
2-Arylaminothiazoles as high-affinity corticotropin-Releasing factor 1 receptor (CRF1R) antagonists: synthesis, binding studies and behavioral efficacy
- 26 September 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (22) , 3997-4000
2-Arylaminothiazoles as high-affinity corticotropin-Releasing factor 1 receptor (CRF1R) antagonists: synthesis, binding studies and behavioral efficacy
- 1 May 2003
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 52 (5) , 328-337
Monoclonal antibody drug immunoconjugates for targeted treatment of cancer
Monoclonal antibodies (mAb) directed to tumor-associated antigens (TAA) or antigens differentially expressed on the tumor vasculature have been covalently linked to drugs that have different mechanisms of action and various levels of potency. The use of these mAb immunoconjugates to selectively deliver drugs to tumors has the potential to both improve antitumor efficacy and reduce the systemic toxicity of therapy. Several immunoconjugates, particularly those that incorporate internalizing antibodies and tumor-selective linkers, have demonstrated impressive activity in preclinical models. Immunoconjugates that deliver doxorubicin, maytansine and calicheamicin are currently being evaluated in clinical trials. The feasibility of using immunoconjugates as cancer therapeutics has been clearly demonstrated. Gemtuzumab ozogamicin, a calicheamicin conjugate that targets CD33, has recently been approved by the Food and Drug Administration (FDA) for treatment of acute myelogenous leukemia (AML). This review concentrates on the properties of the tumor and the characteristics of the mAb, linker, and drugs that influence the efficacy, potency, and selectivity of immunconjugates selected for cancer treatment.
- 1 May 2003
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 52 (5) , 328-337
Monoclonal antibody drug immunoconjugates for targeted treatment of cancer
Monoclonal antibodies (mAb) directed to tumor-associated antigens (TAA) or antigens differentially expressed on the tumor vasculature have been covalently linked to drugs that have different mechanisms of action and various levels of potency. The use of these mAb immunoconjugates to selectively deliver drugs to tumors has the potential to both improve antitumor efficacy and reduce the systemic toxicity of therapy. Several immunoconjugates, particularly those that incorporate internalizing antibodies and tumor-selective linkers, have demonstrated impressive activity in preclinical models. Immunoconjugates that deliver doxorubicin, maytansine and calicheamicin are currently being evaluated in clinical trials. The feasibility of using immunoconjugates as cancer therapeutics has been clearly demonstrated. Gemtuzumab ozogamicin, a calicheamicin conjugate that targets CD33, has recently been approved by the Food and Drug Administration (FDA) for treatment of acute myelogenous leukemia (AML). This review concentrates on the properties of the tumor and the characteristics of the mAb, linker, and drugs that influence the efficacy, potency, and selectivity of immunconjugates selected for cancer treatment.
- 18 June 2002
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 13 (4) , 855-869
Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity
The anticancer drug doxorubicin (DOX) has been linked to chimeric BR96, an internalizing monoclonal antibody that binds to a Lewisy-related, tumor-associated antigen, through two lysosomally cleavable dipeptides, Phe-Lys and Val-Cit, giving immunoconjugates 72 and 73. A self-immolative p-aminobenzyloxycarbonyl (PABC) spacer between the dipeptides and the DOX was required for rapid and quantitative generation of free drug. DOX release from model substrate Z-Phe-Lys-PABC-DOX 49 was 30-fold faster than from Z-Val-Cit-PABC-DOX 42 with the cysteine protease cathepsin B alone, but rates were identical in a rat liver lysosomal preparation suggesting the participation of more than one enzyme. Conjugates 72 and 73 showed rapid and near quantitative drug release with cathepsin B and in a lysosomal preparation, while demonstrating excellent stability in human plasma. Against tumor cell lines with varying levels of BR96 expression, both conjugates showed potent, antigen-specific cytotoxic activity, suggesting that they will be effective in delivering DOX selectively to antigen-expressing carcinomas.
- 18 June 2002
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 13 (4) , 855-869
Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity
The anticancer drug doxorubicin (DOX) has been linked to chimeric BR96, an internalizing monoclonal antibody that binds to a Lewisy-related, tumor-associated antigen, through two lysosomally cleavable dipeptides, Phe-Lys and Val-Cit, giving immunoconjugates 72 and 73. A self-immolative p-aminobenzyloxycarbonyl (PABC) spacer between the dipeptides and the DOX was required for rapid and quantitative generation of free drug. DOX release from model substrate Z-Phe-Lys-PABC-DOX 49 was 30-fold faster than from Z-Val-Cit-PABC-DOX 42 with the cysteine protease cathepsin B alone, but rates were identical in a rat liver lysosomal preparation suggesting the participation of more than one enzyme. Conjugates 72 and 73 showed rapid and near quantitative drug release with cathepsin B and in a lysosomal preparation, while demonstrating excellent stability in human plasma. Against tumor cell lines with varying levels of BR96 expression, both conjugates showed potent, antigen-specific cytotoxic activity, suggesting that they will be effective in delivering DOX selectively to antigen-expressing carcinomas.
- 19 April 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (11) , 1529-1532
Doxorubicin immunoconjugates containing bivalent, lysosomally-Cleavable dipeptide linkages
- 19 April 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (11) , 1529-1532
Doxorubicin immunoconjugates containing bivalent, lysosomally-Cleavable dipeptide linkages
- 17 November 2001
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 3 (25) , 3987-3990
2-Aryl-2,2-difluoroacetamide FKBP12 Ligands: Synthesis and X-ray Structural Studies
2-Aryl-2,2-difluoroacetamido-proline and pipecolate esters are high affinity FKBP12 ligands whose rotamase inhibitory activity is comparable to that seen for the corresponding ketoamides. X-ray structural studies suggest that the fluorine atoms participate in discrete interactions with the Phe36 phenyl ring and the Tyr26 hydroxyl group, with the latter resembling a moderate-to-weak hydrogen bond.
- 17 November 2001
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 3 (25) , 3987-3990
2-Aryl-2,2-difluoroacetamide FKBP12 Ligands: Synthesis and X-ray Structural Studies
2-Aryl-2,2-difluoroacetamido-proline and pipecolate esters are high affinity FKBP12 ligands whose rotamase inhibitory activity is comparable to that seen for the corresponding ketoamides. X-ray structural studies suggest that the fluorine atoms participate in discrete interactions with the Phe36 phenyl ring and the Tyr26 hydroxyl group, with the latter resembling a moderate-to-weak hydrogen bond.
- 1 March 2000
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 10 (6) , 559-562
Fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay
- 1 March 2000
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 10 (6) , 559-562
Fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay